All productsCJC-1295 + Ipamorelin
Size
- 10 mg + 10 mg — $70.00 CAD — Available
Research focus
A blend of compounds separately investigated in growth-hormone signalling and ghrelin-receptor research.
In simple words
CJC-1295 + Ipamorelin is a blend of two compounds studied separately in hormone-signalling research. Findings about either ingredient do not establish how the mixture behaves; the CJC-1295 form in this listing is not specified.
Ingredient studies are shown separately. They do not demonstrate the effects, safety or synergy of the combined vial; exact sequences and unlisted proportions are not assumed. The catalogue does not specify the CJC-1295 DAC form; the cited CJC study used a long-acting analogue.
Research references
Reviewed 2026-10-26
Human — two randomized early-phase trials
Healthy adults aged 21–61; participant totals not given in the reviewed abstract.
The long-acting GHRH analogue increased circulating growth hormone and IGF-I in trials lasting 28 and 49 days.
No serious adverse reactions were reported, but these were short studies. The long-acting compound is not interchangeable with products described as no-DAC; this was not a CJC-1295/Ipamorelin combination trial.
PMID 16352683. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Human — randomized phase 2 trial
117 enrolled patients; 114 in safety and modified intention-to-treat analyses.
Researchers tested ghrelin-receptor agonism for postoperative ileus. Primary and secondary efficacy comparisons did not show significant differences from placebo.
Adverse events were frequent in both postoperative groups. This small, mixed surgical population does not support performance claims or a CJC-1295 combination.
PMID 25331030. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Identity search; no unambiguous compound record assigned to this listing. Check forms and synonyms carefully.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about CJC-1295 + Ipamorelin
What is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is a blend of two compounds studied separately in hormone-signalling research. Findings about either ingredient do not establish how the mixture behaves; the CJC-1295 form in this listing is not specified.
What types of research are cited for CJC-1295 + Ipamorelin?
The CJC-1295 + Ipamorelin profile contains the following selected evidence on individual ingredients. This is not a systematic review or a complete inventory of research.
Long-acting CJC-1295 and hormone secretion (2006): Human — two randomized early-phase trials
Publication: Long-acting CJC-1295 and hormone secretionIpamorelin after bowel surgery (2014): Human — randomized phase 2 trial
Publication: Ipamorelin after bowel surgeryWho or what was studied in the selected CJC-1295 + Ipamorelin references?
Long-acting CJC-1295 and hormone secretion (2006): Healthy adults aged 21–61; participant totals not given in the reviewed abstract.
Publication: Long-acting CJC-1295 and hormone secretionIpamorelin after bowel surgery (2014): 117 enrolled patients; 114 in safety and modified intention-to-treat analyses.
Publication: Ipamorelin after bowel surgeryDo the selected studies test the exact CJC-1295 + Ipamorelin blend?
Ingredient studies are shown separately. They do not demonstrate the effects, safety or synergy of the combined vial; exact sequences and unlisted proportions are not assumed. The catalogue does not specify the CJC-1295 DAC form; the cited CJC study used a long-acting analogue.
What do the selected CJC-1295 + Ipamorelin studies not establish?
Long-acting CJC-1295 and hormone secretion (2006): No serious adverse reactions were reported, but these were short studies. The long-acting compound is not interchangeable with products described as no-DAC; this was not a CJC-1295/Ipamorelin combination trial.
Publication: Long-acting CJC-1295 and hormone secretionIpamorelin after bowel surgery (2014): Adverse events were frequent in both postoperative groups. This small, mixed surgical population does not support performance claims or a CJC-1295 combination.
Publication: Ipamorelin after bowel surgeryThese studies do not establish the identity, purity, safety or effects of the MXC CJC-1295 + Ipamorelin vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.